Veru Inc

NASDAQ:VERU  
7.53
+0.28 (+3.86%)
Regulatory, Other Pre-Announcement

Veru Expands Oncology Drug Pipeline, Exclusively Licenses Phase 3 Clinical Stage Targeted Therapy For Endocrine Resistant Metastatic Breast Cancer

Published: 12/09/2020 12:06 GMT
Veru Inc (VERU) - Veru Expands Oncology Drug Pipeline; Exclusively Licenses Phase 3 Clinical Stage Targeted Therapy for Endocrine Resistant Metastatic Breast Cancer.
Veru Inc - Poised to Initiate Four Oncology Drug Registration Trials in Prostate and Breast Cancer in Calendar Year 2021.
Veru Inc - Expects to Have Sufficient Resources to Fund All Clinical Development to End of FY 2022.